Amedeo Smart

Free Medical Literature Service


 

Amedeo

HIV Infection

  Free Subscription

13.11.2017

22 AIDS
1 Antivir Ther
1 BMC Cancer
3 Clin Infect Dis
2 HIV Med
3 J Acquir Immune Defic Syndr
1 J Immunol
6 J Infect Dis
3 J Virol
4 Lancet HIV
4 Lancet Infect Dis
1 Nat Med
7 PLoS Med
11 PLoS One
1 PLoS Pathog
1 Proc Natl Acad Sci U S A
1 Vaccine



    AIDS

  1. LAVENDER KJ, Pace C, Sutter K, Messer RJ, et al
    An advanced BLT-humanized mouse model for extended HIV-1 cure studies.
    AIDS. 2017 Nov 2. doi: 10.1097/QAD.0000000000001674.
    >> Share

  2. FORD N, Migone C, Calmy A, Kerschberger B, et al
    Benefits and risks of rapid initiation of antiretroviral therapy: a systematic review and meta-analysis.
    AIDS. 2017 Nov 2. doi: 10.1097/QAD.0000000000001671.
    >> Share

  3. NICOL MR, Brewers LM, Kashuba AD, Sykes C, et al
    The role of menopause in tenofovir diphosphate and emtricitabine triphosphate concentrations in cervical tissue.
    AIDS. 2017 Nov 2. doi: 10.1097/QAD.0000000000001678.
    >> Share

  4. GATELL JM, Assoumou L, Moyle G, Waters L, et al
    Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk.
    AIDS. 2017;31:2503-2514.
    >> Share

  5. BOIVIN MJ, Barlow-Mosha L, Chernoff M, Laughton B, et al
    Neuropsychological performance in African children with HIV enrolled in a multi-site anti-retroviral clinical trial.
    AIDS. 2017 Nov 2. doi: 10.1097/QAD.0000000000001683.
    >> Share

  6. CID-SILVA P, Margusino-Framinan L, Balboa-Barreiro V, Martin-Herranz I, et al
    Initial treatment response among HIV subtype F infected patients who started antiretroviral therapy based on integrase inhibitors.
    AIDS. 2017 Nov 2. doi: 10.1097/QAD.0000000000001679.
    >> Share

  7. CARRILLO J, Negredo E, Puig J, Molinos-Albert LM, et al
    Memory B cell dysregulation in HIV-1 infected Individuals.
    AIDS. 2017 Nov 2. doi: 10.1097/QAD.0000000000001686.
    >> Share

  8. CANIGLIA EC, Zash R, Jacobson DL, Diseko M, et al
    Emulating a target trial of antiretroviral therapy regimens started before conception and risk of adverse birth outcomes.
    AIDS. 2017 Nov 2. doi: 10.1097/QAD.0000000000001673.
    >> Share

  9. LONGENECKER CT, Sullivan CE, Morrison J, Hileman CO, et al
    The effects of HIV and smoking on aortic and splenic inflammation.
    AIDS. 2017 Nov 2. doi: 10.1097/QAD.0000000000001682.
    >> Share

  10. BARDON VF, Mandelbrot L, Duro D, Dussaux C, et al
    Placental transfer of elvitegravir and cobicistat in an Ex Vivo human cotyledon double perfusion model.
    AIDS. 2017 Nov 2. doi: 10.1097/QAD.0000000000001681.
    >> Share

  11. BURLACU R, Umlauf A, Luca A, Gianella S, et al
    Sex based differences in neurocognitive functioning in HIV infected young adults.
    AIDS. 2017 Nov 2. doi: 10.1097/QAD.0000000000001687.
    >> Share

  12. ENGELHARD EAN, Smit C, Van Dijk PR, Kuijper TM, et al
    Health-related quality of life of people with HIV: an assessment of patient related factors and comparison with other chronic diseasess.
    AIDS. 2017 Nov 2. doi: 10.1097/QAD.0000000000001672.
    >> Share

  13. OLSON A, Bannert N, Sonnerborg A, de Mendoza C, et al
    Temporal trends of transmitted HIV drug resistance in a multinational seroconversion cohort.
    AIDS. 2017 Nov 2. doi: 10.1097/QAD.0000000000001689.
    >> Share

  14. MOCROFT A, Laut K, Reiss P, Gatell J, et al
    Where is the greatest impact of uncontrolled HIV infection on AIDS and non-AIDS events in HIV?
    AIDS. 2017 Nov 3. doi: 10.1097/QAD.0000000000001684.
    >> Share

  15. BEIMA-SOFIE K, Wamalwa D, Maleche-Obimbo E, Lingappa JR, et al
    Toll-Like Receptor (TLR) 9 polymorphism is associated with increased Epstein-Barr virus and Cytomegalovirus acquisition in HIV-exposed infants.
    AIDS. 2017 Nov 2. doi: 10.1097/QAD.0000000000001680.
    >> Share

  16. MCGILLEN JB, Sharp A, Honermann B, Millett G, et al
    Consequences of a changing US strategy in the global HIV investment landscape.
    AIDS. 2017;31:F19-F23.
    >> Share

  17. EDWARDS JK, Cole SR, Hall HI, Mathews WC, et al
    Virologic suppression and CD4 cell count recovery after initiation of raltegravir- or efavirenz- containing HIV treatment regimens.
    AIDS. 2017 Nov 2. doi: 10.1097/QAD.0000000000001668.
    >> Share

  18. KUNIHOLM MH, Liang H, Anastos K, Gustafson D, et al
    Association of a 3' untranslated region polymorphism in proprotein convertase subtilisin/kexin type 9 with HIV viral load and CD4+ levels in HIV/hepatitis C virus coinfected women.
    AIDS. 2017;31:2483-2492.
    >> Share

  19. DHARAN NJ, Cooper DA
    Reducing medical comorbidities associated with long-term HIV infection: beyond optimizing antiretroviral therapy regimens.
    AIDS. 2017;31:2547-2549.
    >> Share

  20. BRENNER BG, Baril JG
    Limiting cardiovascular events associated with HIV and antiretroviral therapy.
    AIDS. 2017;31:2551-2553.
    >> Share

  21. WU UI, Hung CC, Chang SY, Jhong YT, et al
    Neutralizing antiinterferon-gamma autoantibodies causing disseminated Mycobacterium avium complex infection in an HIV-infected patient on successful combination antiretroviral therapy.
    AIDS. 2017;31:2557-2559.
    >> Share

  22. XIA Q, Ning Z, Torian LV
    Should we report the proportion of late HIV diagnoses?
    AIDS. 2017;31:2559-2561.
    >> Share


    Antivir Ther


  23. 19th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV.
    Antivir Ther. 2017;22.
    >> Share


    BMC Cancer

  24. ALLEN-LEIGH B, Uribe-Zuniga P, Leon-Maldonado L, Brown BJ, et al
    Barriers to HPV self-sampling and cytology among low-income indigenous women in rural areas of a middle-income setting: a qualitative study.
    BMC Cancer. 2017;17:734.
    >> Share


    Clin Infect Dis

  25. GIANELLA S, Haw JS, Blumenthal J, Sullivan B, et al
    The Importance of HIV Research for Transgender and Gender Non-Binary Individuals.
    Clin Infect Dis. 2017 Nov 8. doi: 10.1093.
    >> Share

  26. GRIESEL R, Stewart A, van der Plas H, Sikhondze W, et al
    Optimizing Tuberculosis Diagnosis in HIV-Infected Inpatients Meeting the Criteria of Seriously Ill in the WHO Algorithm.
    Clin Infect Dis. 2017 Nov 6. doi: 10.1093.
    >> Share

  27. AOKI A, Sakagami T, Yoshizawa K, Shima K, et al
    Clinical significance of interferon-gamma neutralizing autoantibodies against disseminated nontuberculous mycobacterial disease.
    Clin Infect Dis. 2017 Nov 8. doi: 10.1093.
    >> Share


    HIV Med

  28. YOUNG J, Smith C, Teira R, Reiss P, et al
    Antiretroviral pill count and clinical outcomes in treatment-naive patients with HIV infection.
    HIV Med. 2017 Nov 6. doi: 10.1111/hiv.12562.
    >> Share

  29. HUFF H, Merchant AT, Lonn E, Pullenayegum E, et al
    Vitamin D and progression of carotid intima-media thickness in HIV-positive Canadians.
    HIV Med. 2017 Nov 6. doi: 10.1111/hiv.12563.
    >> Share


    J Acquir Immune Defic Syndr

  30. ONG JJ, Li H, Dan W, Fu H, et al
    Coercion And Hiv Self-Testing In Men Who Have Sex With Men: Implementation Data From A Cross-Sectional Survey In China.
    J Acquir Immune Defic Syndr. 2017 Nov 2. doi: 10.1097/QAI.0000000000001583.
    >> Share

  31. SKAATHUN B, Khanna AS, Morgan E, Friedman SR, et al
    Network Viral Load: A Critical Metric For Hiv Elimination.
    J Acquir Immune Defic Syndr. 2017 Nov 2. doi: 10.1097/QAI.0000000000001584.
    >> Share

  32. EYAWO O, McGinnis KA, Justice AC, Fiellin DA, et al
    Alcohol and Mortality: Combining Self-reported (AUDIT-C) and Biomarker Detected (PEth) Alcohol Measures Among HIV Infected and Uninfected.
    J Acquir Immune Defic Syndr. 2017 Nov 2. doi: 10.1097/QAI.0000000000001588.
    >> Share


    J Immunol

  33. PINDER CL, Kratochvil S, Cizmeci D, Muir L, et al
    Isolation and Characterization of Antigen-Specific Plasmablasts Using a Novel Flow Cytometry-Based Ig Capture Assay.
    J Immunol. 2017 Nov 8. pii: ji1701253. doi: 10.4049/jimmunol.1701253.
    >> Share


    J Infect Dis

  34. AULD SC, Kasmar AG, Dowdy DW, Mathema B, et al
    Research Roadmap for Tuberculosis Transmission Science: Where Do We Go From Here and How Will We Know When We're There?
    J Infect Dis. 2017;216.
    >> Share

  35. NAIDOO P, Theron G, Rangaka MX, Chihota VN, et al
    The South African Tuberculosis Care Cascade: Estimated Losses and Methodological Challenges.
    J Infect Dis. 2017;216.
    >> Share

  36. REID MJA, Goosby E
    Patient-Centered Tuberculosis Programs Are Necessary to End the Epidemic.
    J Infect Dis. 2017;216.
    >> Share

  37. CHURCHYARD G, Kim P, Shah NS, Rustomjee R, et al
    What We Know About Tuberculosis Transmission: An Overview.
    J Infect Dis. 2017;216.
    >> Share

  38. SHAH NS, Kim P, Kana BD, Rustomjee R, et al
    Getting to Zero New Tuberculosis Infections: Insights From the National Institutes of Health/US Centers for Disease Control and Prevention/Bill & Melinda Gates Foundation Workshop on Research Needs for Halting Tuberculosis Transmission.
    J Infect Dis. 2017;216.
    >> Share

  39. MATHEMA B, Andrews JR, Cohen T, Borgdorff MW, et al
    Drivers of Tuberculosis Transmission.
    J Infect Dis. 2017;216.
    >> Share


    J Virol

  40. ELLIS-CONNELL AL, Balgeman AJ, Zarbock KR, Barry G, et al
    ALT-803 transiently reduces SIV replication in the absence of antiretroviral treatment.
    J Virol. 2017 Nov 8. pii: JVI.01748-17. doi: 10.1128/JVI.01748.
    >> Share

  41. PINKEVYCH M, Fennessey CM, Cromer D, Tolstrup M, et al
    Estimating initial viral levels during HIV/SIV reactivation from latency.
    J Virol. 2017 Nov 8. pii: JVI.01667-17. doi: 10.1128/JVI.01667.
    >> Share

  42. QUITADAMO B, Peters PJ, Repik A, O'Connell O, et al
    HIV-1 R5 macrophage-tropic envelope glycoprotein trimers bind CD4 with high affinity, while the CD4 binding site on non-macrophage-tropic, T- tropic R5 envelopes is occluded.
    J Virol. 2017 Nov 8. pii: JVI.00841-17. doi: 10.1128/JVI.00841.
    >> Share


    Lancet HIV

  43. KELLY H, Weiss HA, Benavente Y, de Sanjose S, et al
    Association of antiretroviral therapy with high-risk human papillomavirus, cervical intraepithelial neoplasia, and invasive cervical cancer in women living with HIV: a systematic review and meta-analysis.
    Lancet HIV. 2017 Oct 26. pii: S2352-3018(17)30149.
    >> Share

  44. DE VRIES HJC, Steenbergen RDM
    The effect of ART on cervical cancer precursor lesions.
    Lancet HIV. 2017 Oct 26. pii: S2352-3018(17)30189.
    >> Share

  45. TREVILLYAN JM, Hoy JF
    Dolutegravir monotherapy as maintenance ART bites the dust.
    Lancet HIV. 2017 Oct 26. pii: S2352-3018(17)30168.
    >> Share

  46. WIJTING I, Rokx C, Boucher C, van Kampen J, et al
    Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomised non-inferiority trial.
    Lancet HIV. 2017 Oct 26. pii: S2352-3018(17)30152.
    >> Share


    Lancet Infect Dis

  47. COUSINS S
    HIV and antenatal care in Sri Lanka: a global health success.
    Lancet Infect Dis. 2017;17:1126.
    >> Share

  48. ABEL L, Fellay J, Haas DW, Schurr E, et al
    Genetics of human susceptibility to active and latent tuberculosis: present knowledge and future perspectives.
    Lancet Infect Dis. 2017 Oct 27. pii: S1473-3099(17)30623.
    >> Share

  49. HILL AM, Venter F
    The unexpected success of NRTIs in second-line treatment.
    Lancet Infect Dis. 2017 Nov 3. pii: S1473-3099(17)30631.
    >> Share

  50. HAKIM JG, Thompson J, Kityo C, Hoppe A, et al
    Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial.
    Lancet Infect Dis. 2017 Nov 3. pii: S1473-3099(17)30630.
    >> Share


    Nat Med

  51. BUNDERS MJ, Altfeld M
    Can NK cells purge HIV sanctuaries?
    Nat Med. 2017;23:1254-1255.
    >> Share


    PLoS Med

  52. POTEAT T, Ackerman B, Diouf D, Ceesay N, et al
    HIV prevalence and behavioral and psychosocial factors among transgender women and cisgender men who have sex with men in 8 African countries: A cross-sectional analysis.
    PLoS Med. 2017;14:e1002422.
    >> Share

  53. EL-SADR WM, Harripersaud K, Rabkin M
    Reaching global HIV/AIDS goals: What got us here, won't get us there.
    PLoS Med. 2017;14:e1002421.
    >> Share

  54. KAPLAN SR, Oosthuizen C, Stinson K, Little F, et al
    Contemporary disengagement from antiretroviral therapy in Khayelitsha, South Africa: A cohort study.
    PLoS Med. 2017;14:e1002407.
    >> Share

  55. HENRICH TJ, Hatano H, Bacon O, Hogan LE, et al
    HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study.
    PLoS Med. 2017;14:e1002417.
    >> Share

  56. BOYD MA, Mocroft A, Ryom L, Monforte AD, et al
    Cardiovascular disease (CVD) and chronic kidney disease (CKD) event rates in HIV-positive persons at high predicted CVD and CKD risk: A prospective analysis of the D:A:D observational study.
    PLoS Med. 2017;14:e1002424.
    >> Share

  57. MCNAIRY ML, Lamb MR, Gachuhi AB, Nuwagaba-Biribonwoha H, et al
    Effectiveness of a combination strategy for linkage and retention in adult HIV care in Swaziland: The Link4Health cluster randomized trial.
    PLoS Med. 2017;14:e1002420.
    >> Share

  58. CASTILLO P, Hurtado JC, Martinez MJ, Jordao D, et al
    Validity of a minimally invasive autopsy for cause of death determination in maternal deaths in Mozambique: An observational study.
    PLoS Med. 2017;14:e1002431.
    >> Share


    PLoS One

  59. WIRTH KE, Semo BW, Spees LP, Ntsuape C, et al
    A prospective cohort study of safety and patient satisfaction of voluntary medical male circumcision in Botswana.
    PLoS One. 2017;12:e0185904.
    >> Share

  60. FOKAM J, Billong SC, Jogue F, Moyo Tetang Ndiang S, et al
    Immuno-virological response and associated factors amongst HIV-1 vertically infected adolescents in Yaounde-Cameroon.
    PLoS One. 2017;12:e0187566.
    >> Share

  61. KABORE FN, Eymard-Duvernay S, Zoungrana J, Badiou S, et al
    TDF and quantitative ultrasound bone quality in African patients on second line ART, ANRS 12169 2LADY sub-study.
    PLoS One. 2017;12:e0186686.
    >> Share

  62. MANINENG CM, MacLaren D, Baigry M, Trowalle E, et al
    Re-establishing safer medical-circumcision-integrated initiation ceremonies for HIV prevention in a rural setting in Papua New Guinea. A multi-method acceptability study.
    PLoS One. 2017;12:e0187577.
    >> Share

  63. MUKOSWA GM, Charalambous S, Nelson G
    The association between social capital and HIV treatment outcomes in South Africa.
    PLoS One. 2017;12:e0184140.
    >> Share

  64. CHHOUN P, Tuot S, Harries AD, Kyaw NTT, et al
    High prevalence of non-communicable diseases and associated risk factors amongst adults living with HIV in Cambodia.
    PLoS One. 2017;12:e0187591.
    >> Share

  65. BEEN SK, Yildiz E, Nieuwkerk PT, Pogany K, et al
    Self-reported adherence and pharmacy refill adherence are both predictive for an undetectable viral load among HIV-infected migrants receiving cART.
    PLoS One. 2017;12:e0186912.
    >> Share

  66. KONERMAN MA, Lu D, Zhang Y, Thomson M, et al
    Assessing risk of fibrosis progression and liver-related clinical outcomes among patients with both early stage and advanced chronic hepatitis C.
    PLoS One. 2017;12:e0187344.
    >> Share

  67. NZUZA S, Zondi S, Owira PMO
    Naringin prevents HIV-1 protease inhibitors-induced metabolic complications in vivo.
    PLoS One. 2017;12:e0183355.
    >> Share

  68. ARMSTRONG-HOUGH M, Turimumahoro P, Meyer AJ, Ochom E, et al
    Drop-out from the tuberculosis contact investigation cascade in a routine public health setting in urban Uganda: A prospective, multi-center study.
    PLoS One. 2017;12:e0187145.
    >> Share

  69. LONGO JD, Simaleko MM, Diemer HS, Gresenguet G, et al
    Risk factors for HIV infection among female sex workers in Bangui, Central African Republic.
    PLoS One. 2017;12:e0187654.
    >> Share


    PLoS Pathog

  70. MACKELPRANG RD, Bamshad MJ, Chong JX, Hou X, et al
    Whole genome sequencing of extreme phenotypes identifies variants in CD101 and UBE2V1 associated with increased risk of sexually acquired HIV-1.
    PLoS Pathog. 2017;13:e1006703.
    >> Share


    Proc Natl Acad Sci U S A

  71. PAK AJ, Grime JMA, Sengupta P, Chen AK, et al
    Immature HIV-1 lattice assembly dynamics are regulated by scaffolding from nucleic acid and the plasma membrane.
    Proc Natl Acad Sci U S A. 2017 Nov 7. pii: 201706600.
    >> Share


    Vaccine

  72. NANNI A, Meredith S, Gati S, Holm K, et al
    Strengthening global vaccine access for adolescents and adults.
    Vaccine. 2017 Nov 6. pii: S0264-410X(17)31419.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016